替吉奥胶囊联合奥沙利铂新辅助化疗治疗进展期胃癌的疗效观察  

Observation of the effect of neoadjuvant chemotherapy of tegafur gimeracfl oteracil potassium capsule combined with oxaliplatin in treatment of advanced gastric cancer

作　　者：邱守田[1] 任杰远[2] 戴学虎 

机构地区：[1]滨州市中心医院药剂科,山东省滨州251700 [2]滨州市中心医院消化内科,山东省滨州251700

出　　处：《中国基层医药》2016年第3期400-404,共5页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨替吉奥胶囊联合奥沙利铂新辅助化疗治疗进展期胃癌的有效性和不良反应。方法采用随机数字表法将70例进展期胃癌患者分为两组：研究组和对照组，每组患者各35例。研究组患者采用替吉奥胶囊联合奥沙利铂新辅助化疗治疗，对照组患者采用FOLFOX治疗方案。分别治疗3个周期后，观察并比较两组患者的治疗疗效以及不良反应发生情况。结果研究组总有效率为71．43％，显著高于对照组的45．71％（16／35）（x2=5．02，P〈0．05）。CD8、CIM／CD8研究组放疗前后比较差异有统计学意义（P〈0．05）。对照组治疗前后WBC、中性粒细胞差异有统计学意义（P〈0．05）；CD8，CD4／CD8及中性粒细胞治疗后研究组显著高于对照组（P〈0．05）。对照组消化道不良反应的发生率显著高于研究组（x2=3．75、4．02，均P〈0．05）。研究组治疗后1年生存率为85．71％、2年生存率为57．14％，1年复发率为20．00％，2年复发率为40．00％，对照组治疗后1年生存率为71．43％、2年生存率为42．86％，1年复发率为22．86％，2年复发率为42．86％，两组比较差异均无统计学意义（x2=1．02、0．79、0．90、1．05，P〉0．05）。结论吉奥胶囊联合奥沙利铂新辅助化疗治疗进展期胃癌疗效好，毒副反应小，安全性高。Objective To explore the effect and toxicity of S - 1 combined with oxaliplatin neoadjuvant chemotherapy in treatment of advanced gastric cancer. Methods 70 patients with gastric cancer were divided into the study group and the control group by using the random number table method ,35 cases in each group. The study group was given neoadjuvant chemotherapy with S - 1 combined with oxaliplatin, and the control group was treated with FOLFOX regimen. After three cycles of treatment, the effect and the toxicity of the two groups were observed and com- pared. Results The total effective rate of the study group was 71.43 %, which was significantly higher than 45.71% （16/35） of the control group （X2 = 5.02, P 〈 0.05 ）. The CD8 and CD4/CD8 in the study group before and after radiotherapy had statistically significant difference （ P 〈 0.05 ）. WBC and neutrophils in the control group had significant difference before and after treatment （ P 〈 O. 05 ）, CD8, CD4/CD8 in the study group were significantly higher than those in control group （ P 〈 0.05 ）. The incidence of gastrointestinal adverse reactions in the control group was significantly higher than that in the study group （ X2 = 3.75.4.02, all P 〈 O. 05 ）. The 1 year survival rate in the study group was 85.71% ,2 years survival rate was 57. 14%, the recurrence rates of 1 year and 2 years were 20. 00% ,40.00% ,which in the control group were 71.43% ,42.86% ,22.86% ,42.86% ,the differences were not statistically significant （ X2 = 1.02,0.79,0.90,1.05, all P 〉 0.05 ）. Conclusion S - 1 combined with oxaliplatin neoadjuvant chemotherapy has good effect in treatment of advanced gastric cancer,the side reaction is small, with high safety.

关 键 词：替吉奥胶囊 奥沙利铂 进展期胃癌 疗效 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]